Insecticides India Q1FY27 Revenue Declines 12% to ₹612 Crore Amidst Rainfall Deficit
Insecticides (India) Limited reported Q1FY27 revenue of ₹612 crore, down 12% YoY due to rainfall deficit. Gross profit margins expanded 240 bps. The company launched GRANUVIA and Spinoace in collaboration with Corteva Agriscience. IIL plans to double its Crop Solutions plots and remains confident in future growth.
The 12% revenue decline is significant, but the expansion in gross profit margins and strategic product launches suggest resilience. The impact is medium as it reflects current challenges but also points to future growth potential.
While revenue declined due to external factors like rainfall deficit, the company managed to expand gross profit margins and launched new products. The management expressed confidence in future performance, indicating a neutral sentiment.
Insecticides (India) Limited (IIL) has announced its unaudited financial results for the first quarter and three months ended June 30, 2026. The company reported a revenue of ₹612 crore in Q1FY27, a decrease of 12% compared to ₹691 crore in Q1FY26. This decline is primarily attributed to a rainfall deficit across India.
Despite the revenue dip, gross profit margins expanded by 240 basis points year-on-year due to disciplined pricing actions. The company also highlighted the pan-India launch of GRANUVIA, a next-generation insecticide developed in collaboration with Corteva Agriscience, and the introduction of Spinoace during the quarter. The product KAEROS continued its strong performance, expanding its portfolio and distribution. IIL plans to double the number of its Crop Solutions (ICS plots) to 72, covering four major crops across 14 states.
Key financial highlights for Q1FY27 include revenue from operations at ₹612 crore, a decrease from ₹691 crore in Q1FY26. Gross Profit stood at ₹193 crore, down from ₹202 crore, with Gross Profit Margin at 31.6% compared to 29.2% YoY. EBITDA was ₹68 crore, a 20% decrease from ₹85 crore, and Profit After Tax was ₹44 crore, down 24% from ₹58 crore in the prior year period.
Mr. Rajesh Kumar Aggarwal, MD of Insecticides (India) Ltd., commented that the company delivered a resilient performance despite subdued demand, supported by its diversified product portfolio and strong execution. He expressed confidence in building momentum through the coming quarters, supported by sustained investments in premiumization, manufacturing, research, digital transformation, and global partnerships. The expansion of its Focus Maharatna and Maharatna portfolios, along with collaborations with global innovators, is strengthening margins and farmer engagement. Kaeros Research is evolving into a significant growth platform, and the company is advancing its international business footprint. Supported by capacity expansion, backward integration, and operational excellence, IIL is building a more resilient and future-ready organization.
What to do with a filing like this
Insecticides (India) Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Insecticides (India) Limited. Read the original for the full detail.